For many years there has been little interest and research into sarcoidosis by pharmaceutical companies. That is now changing. New clinical trials specifically designed for sarcoidosis are taking place in the UK as well as USA and other countries. Find out more on our Clinical Trials in Sarcoidosis Webpage.
The Xentria trial is a Phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis. See below for information about the trial sites for this clinical trial:
University Hospitals Coventry and Warwickshire NHS Trust
University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX
Email: clinicaltrials@stopsarcoidosis.org
Principal Investigator: Beatriz Lara Gallego, MD
University College Hospitals NHS Foundation Trust
University College Hospitals, London, NW1 2PG
Email: clinicaltrials@stopsarcoidosis.org
Principal Investigator: Joanna Porter, MD
King’s College Hospital NHS Foundation Trust
King’s College Hospital, London, SE5 9RS
Email: clinicaltrials@stopsarcoidosis.org
Principal Investigator: James Galloway, MD
Norfolk and Norwich University Hospitals NHS Foundation Trust
Norfolk and Norwich University Hospitals, Norwich, NR4 7UY
Email: clinicaltrials@stopsarcoidosis.org
Principal Investigator: Andrew M Wilson, MD
Oxford University Hospitals NHS Foundation Trust
Oxford University Hospitals, Oxford, OX3 7LE
Email: clinicaltrials@stopsarcoidosis.org
Principal Investigator: Ling-Pei Ho, MD
NHS Tayside
Perth, Scotland, PH1 1NX
Email: clinicaltrials@stopsarcoidosis.org
Principal Investigator: Mark Spears, MD